Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.

Acta biochimica et biophysica Sinica - 30 May 2024

Zhang Shaoqin, Xue Xuezhen, Chen Fengdan, Yang Yahan, Zhang Nan, Chen Yan, Wu Wenda, Wang Jichuang, Zheng Ning

Abstract excerpt

Systemic therapies, the ultimate strategies for patients with advanced hepatocellular carcinoma (HCC), are suffering from serious clinical challenges, such as the occurrence and development of drug resistance. Treatment resistance aggravates tumor progression partly by inducing tumor metastasis. Regorafenib-resistant HCC cells exhibit a highly striking metastatic phenotype, but the detailed mechanisms underlying...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Liver Neoplasms

Share to Mice, Nude

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 38818582
DOI: 10.3724/abbs.2024058
PMCID: PMC11322875

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.PMID 38818582Read ↗

Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.Semantic proximity Read ↗

A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancerSemantic proximity Read ↗

The role of GLI1 for 5-Fu resistance in colorectal cancerSemantic proximity Read ↗

FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer CellsSemantic proximity Read ↗

Discovery and Validation of COL11A1 as a Therapeutic Target for Sorafenib Resistance in Lung AdenocarcinomaSemantic proximity Read ↗

Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.Semantic proximity Read ↗

Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular TumorsSemantic proximity Read ↗

Low protein expression of LZTR1 in hepatocellular carcinoma triggers tumorigenesis via activating the RAS/RAF/MEK/ERK signalingSemantic proximity Read ↗

POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.Semantic proximity Read ↗

Gly-tRF Enhances LCSCs-Like Cells Stemness and Promotes EMT of HCC Cells via Targeting NDFIP2 and Activating AKT Signaling Pathway.Semantic proximity Read ↗

Long Non-coding RNA MAFG-AS1 Promotes Cell Proliferation, Migration, and EMT by miR-3196/STRN4 in Drug-Resistant Cells of Liver CancerSemantic proximity Read ↗

Frizzled 2‐induced epithelial‐mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.